R&D Sponsored AI can give drug hunters more answers. The real advantage is... The most useful question is not if AI can make drug discovery faster: it is whether it can help scientists learn quicker and make better decisions.
Digital Sponsored Ethical AI & trust-driven innovation: UCB’s Erik Janssen How can pharma lead the way in ethical AI and trust-driven innovation?
News White House signs pricing deals with nine more pharmas Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.
News EULAR 26 hears of treatment advances in lupus Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.
R&D Why UCB bet a billion dollars on cell therapy for epilepsy UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.
R&D Sponsored 12 Questions With Marie Teil Marie Teil is a pharmaceutical executive with over 20 years of experience in the healthcare field. She leads UCB's Women of Childbearing Age programme
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.